JAK2 and acute lymphoblastic leukemia: This suggests the activation of alternative signaling pathways, such as RAS/MAPK, PI3K/PKB and mTOR, arguing against JAK2 inhibition as a precision medicine strategy for in CRLF2r/JAK2-mutant ALL (Winter et al., 2014; Tasian SK.